3SBio Inc. — Board/Management Information 2016

Apr 25, 2016

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

3SBIO INC.

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1530)

ANNOUNCEMENT

RE-APPOINTMENTS OF NON-EXECUTIVE DIRECTORS AND INDEPENDENT NON-EXECUTIVE DIRECTORS

Re-appointment of Non-executive Directors

The board of directors (the “ Board ”) of 3SBio Inc. (the “ Company ”) is pleased to announce that, due to the terms of appointment of the following non-executive directors of the Company expiring soon, Mr. LIU Dong ( 劉東 ) (“ Mr. Liu ”) and Mr. LV Dong ( 呂東 ) (“ Mr. Lv ”) have been reappointed as non-executive directors of the Company (the “ Non-executive Directors ”).

The term of office of the Non-executive Directors shall commence from the date of their respective appointment letters (being April 25, 2016) to the date of the second annual general meeting of the Company since the date of the appointment letters, subject to re-election and retirement as required by the Company’s articles of association (the “ Articles of Association ”), for nil remuneration.

Biographical details of each of the Non-executive Directors are set out as follows:

Mr. LIU Dong , aged 43, has been a non-executive director of the Company since November 27, 2014. He is responsible for participating in the formulation of the Company’s corporate and business strategies. Mr. Liu has served as a director of Shenyang Sunshine Pharmaceutical Company Limited ( 瀋陽三生製藥有限責任公司 ) (“ Shenyang Sunshine ”) since May 28, 2013.

1

Mr. Liu joined CITIC Private Equity Funds Management Co., Ltd (“ CITIC PE ”) in January 2009. He is a managing director of CITIC PE in charge of investment in the healthcare sector. Mr. Liu also currently serves as a director of Zhejiang Beingmate Technology Industry & Trade Co. Ltd. ( 浙江貝因美科工貿股份有限公司 ) (a company listed on the Shenzhen Stock Exchange with stock code 002570), Biosensors International Group, Ltd. (a company listed on the SGX-ST with symbol B20) and Luye Pharma Group Ltd. (a company listed on The Stock Exchange of Hong Kong Limited with stock code 2186). Mr. Liu received a joint Bachelor’s degree in Physics and Finance from Nankai University ( 南開大學 ) in June 1995 and an Executive Master of Business Administration from China Europe International Business School ( 中歐國際工商學院 ) in October 2011.

Mr. LV Dong , aged 41, has been a non-executive director of the Company since November 27, 2014. He is responsible for participating in the formulation of the Company’s corporate and business strategies. Mr. Lv has served as a director of Shenyang Sunshine since May 28, 2013. He was appointed as a supervisor of Jiuzhitang Co., Ltd. ( 九芝堂股份有限公司 ) (a company listed on the Shenzhen Stock Exchange with stock code 000989) in 2015. Mr. Lv has also served as a vice president of CITIC PE, mainly engaging in the investment in the healthcare sector, since 2011. Mr. Lv received a Master’s degree in Pharmacy from Peking University ( 北京大學 ) in 2003 and a Doctorate degree in Pharmaceutical Administration from China Pharmaceutical University ( 中國藥 科大學 ) in June 2010.

Re-appointment of Independent Non-executive Directors

The Board is also pleased to announce that, due to the terms of appointment of the following independent non-executive directors of the Company expiring soon, Mr. PU Tianruo ( 濮天 若 ) (“ Mr. Pu ”), Mr. David Ross PARKINSON (“ Mr. Parkinson ”) and Mr. MA Jun ( 馬駿 ) (“ Mr. Ma ”) have been re-appointed as independent non-executive directors of the Company (the “ Independent Non-executive Directors ”).

The term of office of the Independent Non-executive Directors shall commence from the date of their respective appointment letters (being April 25, 2016) to the end of three years since the date of the next annual general meeting of the Company, subject to re-election and retirement as required by the Articles of Association, for an annual director’s fee of HK$300,000.

Biographical details of each of the Independent Non-executive Directors are set out as follows:

Mr. PU Tianruo , aged 47, has been an independent non-executive director of the Company since June 1, 2015. He is responsible for participating in decision-making and advising on issues relating to the Company’s significant events and corporate governance. Previously, he served as an independent director, the audit committee chair and a compensation committee member of the Company from September 1, 2012 to May 29, 2013.

2

Mr. Pu has had substantial experience in corporate finance, accounting, mergers and acquisitions, as well as in the technology sector. He has served as an independent non-executive director of WOWO Limited (a company listed on the NASDAQ Global Market (“ NASDAQ ”) with symbol WOWO) since April 2015. He served as director and chief financial officer of UTStarcom (a company listed on the NASDAQ with symbol UTSI) from November 2011 to May 2014 and from October 2012 to August 2014, respectively. Mr. Pu also served as the chief financial officer of China Nuokang Bio-Pharmaceutical Inc. (a company listed on the NASDAQ with symbol NKBP) from September 2008 to June 2012. Mr. Pu obtained a Bachelor’s degree in English from China Foreign Affairs University ( 外交學院 ) in July 1991, a Master’s degree in Accounting from the University of Illinois, College of Business Administration in May 1996 and a Master of Business Administration from Northwestern University Kellogg School of Management in June 2000.

Mr. David Ross PARKINSON , aged 66, has been an independent non-executive director of the Company since June 1, 2015. He is responsible for participating in decision-making and advising on issues relating to the Company’s significant events and corporate governance.

Mr. Parkinson has served as a director of ESSA Pharma Inc. (a company listed on the NASDAQ with symbol EPIX) since June 2015, a director of Cerulean Pharma, Inc. (a company listed on the NASDAQ with symbol CERU) since November 2014 and Threshold Pharmaceuticals, Inc. (a company listed on the NASDAQ with symbol THLD) since May 2010. He was appointed as the president and chief executive officer of ESSA Pharma Inc. in January 2016. He has also served as a director of DeNovo Biosciences, Inc. and Tocagen Inc. and is a venture partner at New Enterprise Associates, a venture capital firm. From 2007 to 2012, Mr. Parkinson served as president and chief executive officer at Nodality, Inc., a biotechnology company focused on personalized medicine. Before that, he was a vice president and head of the clinical oncology therapeutic area at Amgen Inc. (a company listed on the NASDAQ with symbol AMGN). Mr. Parkinson served as a director of the American Association for Cancer Research (AACR) from 2006 to 2009. He served on the National Cancer Policy Forum of the Institute of Medicine from 2005 to 2011. Mr. Parkinson has received multiple awards and honors, including the top innovator award from the Multiple Myeloma Research Foundation in 2012 and the Wiley Medal from the United States Food and Drug Administration in 1997. He delivered the 12th Andrew H. Weinberg Memorial Lecture at the Harvard University School of Medicine in 2008. Mr. Parkinson obtained a Doctor of Medicine degree (M.D.) at the University of Toronto Faculty of Medicine in 1974.

Mr. MA Jun , aged 53, has been an independent non-executive director of the Company since the June 1, 2015. He is responsible for participating in decision-making and advising on issues relating to the Company’s significant events and corporate governance. Mr. Ma has served as the chief executive officer of Rong & De (Tianjin) Investment Partnership (Limited Partnership) ( 熔安德 ( 天 律 ) 投資合夥企業 ( 有限合夥 )) since April 2011, in charge of fund raising and management. Mr. Ma was an attorney of Commerce & Finance Law Offices from January 2006 to April 2007.

Mr. Ma obtained a Bachelor of Laws degree (L.L.B.) from Peking University ( 北京大學 ) in July 1985. He obtained a Juris Doctor degree (J.D.) from Cornell Law School in May 1996 and was subsequently admitted to the New York bar.

Each of the Independent Non-executive Directors has confirmed that he continues to meet the independence criteria as set out in Rule 3.13 of the Listing Rules.

3

Save as disclosed above, the Board is not aware of any other information relating to the Nonexecutive Directors and the Independent Non-executive Directors which is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules. There is no other matter which needs to be brought to the attention of the shareholders of the Company in respect of the re-appointments.

By order of the Board 3SBio Inc. Mr. LOU Jing Chairman

Hong Kong, April 25, 2016

As at the date of this announcement, the Board comprises Mr. LOU Jing, Mr. TAN Bo, Ms. SU Dongmei and Mr. HUANG Bin as executive directors; Mr. LIU Dong and Mr. LV Dong as non-executive directors; and Mr. PU Tianruo, Mr. David Ross PARKINSON and Mr. MA Jun as independent non-executive directors.

4